All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Fosifloxuridine Nafalbenamide,Leucovorin Calcium
Therapeutic Area: Oncology Product Name: NUC-3373
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2021
Details:
10 patient out of 37 case studies highlighted NUC-3373’s ability to stabilize disease and achieve prolonged durations of progression-free survival. Many patients achieved longer progression-free survival on NUC-3373 than they had on their prior line of therapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Datopotamab deruxtecan
Therapeutic Area: Oncology Product Name: DS-1062
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2021
Details:
Data for datopotamab deruxtecan (DS-1062) and ENHERTU® signal strong potential of these antibody drug conjugates in advanced lung cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AZD9833,Palbociclib
Therapeutic Area: Oncology Product Name: AZD9833
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
New data from the SERENA-1 Phase I trial show strong efficacy and safety profile for next-generation oral SERD AZD9833 in HR-positive advanced breast cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MRx0518
Therapeutic Area: Oncology Product Name: MRx0518
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Following MRx0518 treatment, relative increases in cytotoxic cells, CD8+ T cells and other immune subsets associated with anti-tumor activity were observed in paired tumor samples.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Berubicin Hydrochloride
Therapeutic Area: Oncology Product Name: RTA 744
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: CNS Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 24, 2020
Details:
IAG, a leading medical imaging company, will work closely with CNS during the Berubicin clinical trials to provide critical imaging services, its proprietary platform DYNAMIKA and imaging data analysis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Patritumab Deruxtecan,Osimertinib
Therapeutic Area: Oncology Product Name: U3-1402
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Daiichi Sankyo Co Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 06, 2020
Details:
The collaboration aims to evaluate the combination of patritumab deruxtecan (U3-1402) and TAGRISSO (osimertinib) in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer (NSCLC).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Etigilimab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: OrbiMed
Deal Size: $70.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 04, 2020
Details:
Along with this private placement, Mereo plans to advance etigilimab (Anti-TIGIT) into a Phase 1b study alongside progressing its rare disease product portfolio, based on the Company’s existing promising clinical data with etigilimab.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MTL-CEBPA,Sorafenib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
Details:
Observed clinical activity, including durable and complete tumour responses, suggests that MTL-CEBPA may increase the effectiveness of sorafenib standard of care.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Panobinostat lactate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 18, 2020
Details:
The cash raised will be used to fund Midatech's MTX110 clinical programme, the development of an internal pipeline of Q-Sphera formulations for partnering, and for general corporate purposes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CUE-101
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Cue Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 14, 2020
Details:
This strategic collaboration will exploit the state-of-the art technologies pioneered by Dr. Dustin’s lab to elucidate the immune synapse interactions of Cue Biopharma's IL-2-based CUE-100 series that ultimately result in selective activation of tumor-antigen-specific T cells.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
